NASDAQ:URGN Urogen Pharma (URGN) Stock Price, News & Analysis $36.83 -0.15 (-0.41%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$36.83 0.00 (-0.01%) As of 10/9/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Urogen Pharma Stock (NASDAQ:URGN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Urogen Pharma alerts:Sign Up Key Stats Today's Range$36.69▼$38.1150-Day Range$36.83▼$50.2952-Week Range$15.86▼$50.81Volume3.90 million shsAverage Volume814,161 shsMarket Capitalization$1.80 billionP/E RatioN/ADividend YieldN/APrice Target$52.38Consensus RatingModerate Buy Company Overview UroGen Pharma Ltd. is a biopharmaceutical company focused on developing and commercializing therapies for cancers of the urinary tract. The company’s platform is based on RTGel, a proprietary reverse-thermal hydrogel designed to retain medicines in the urinary tract and provide localized treatment while limiting systemic exposure. UroGen’s lead commercial product is JELMYTO (mitomycin), a gel-based therapy approved by the U.S. Food and Drug Administration for the primary chemoablation of low-grade upper tract urothelial cancer in adults. The company is also developing UGN-102, an investigational formulation of mitomycin intended for the treatment of low-grade, intermediate-risk non-muscle-invasive bladder cancer. Founded in 2004, UroGen is headquartered in Princeton, New Jersey, and has operations connected to Israel, where the company was established. Its commercial activities are primarily focused on the United States, while its clinical development programs are intended to support broader treatment options for patients with urological cancers. Elizabeth Barrett serves as the company’s president and chief executive officer.AI Generated. May Contain Errors. Read More Urogen Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks64th Percentile Overall ScoreURGN MarketRank™: Urogen Pharma scored higher than 64% of companies evaluated by MarketBeat, and ranked 498th out of 883 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingUrogen Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.70, and is based on no strong buy ratings, 8 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialUrogen Pharma has a consensus price target of $52.38, representing about 42.2% upside from its current price of $36.83.Amount of Analyst CoverageUrogen Pharma has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Urogen Pharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Urogen Pharma are expected to grow in the coming year, from ($0.20) to $3.49 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Urogen Pharma is -18.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Urogen Pharma is -18.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Urogen Pharma's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted16.69% of the float of Urogen Pharma has been sold short.Short Interest Ratio / Days to CoverUrogen Pharma has a short interest ratio ("days to cover") of 9.91.Change versus previous monthShort interest in Urogen Pharma has recently increased by 24.32%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldUrogen Pharma does not currently pay a dividend.Dividend GrowthUrogen Pharma does not have a long track record of dividend growth. News and Social Media3.5 / 5News Sentiment0.59 News SentimentUrogen Pharma has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Urogen Pharma this week, compared to 3 articles on an average week.Search Interest3 people have searched for URGN on MarketBeat in the last 30 days. MarketBeat Follows8 people have added Urogen Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 14% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Urogen Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,037,646.00 in company stock.Percentage Held by Insiders4.80% of the stock of Urogen Pharma is held by insiders.Percentage Held by Institutions91.29% of the stock of Urogen Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Urogen Pharma's insider trading history. Receive URGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Urogen Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. URGN Stock News HeadlinesUrogen Pharma (NASDAQ:URGN) CFO Chris Degnan Sells 2,202 Shares of StockOctober 10 at 6:07 AM | insidertrades.comUroGen Pharma (URGN) Stock Looks Fairly Valued On Its Sales BaseSeptember 25, 2026 | finance.yahoo.comFirst Look: Elon’s “Starphone”Rumors are swirling that Elon Musk is developing a new mobile device that could rival the iPhone. It's said to be thinner, longer-lasting on battery, and cheaper to produce, with the ability to work worldwide without relying on cell towers. Former Bloomberg reporter and SAC Capital trader Josh Baylin says the evidence is mounting. He notes the FCC recently gave Musk a green light connected to his mobile plans, adding fuel to speculation. Baylin previously called the smartphone boom in 2004 and predicted Apple would sell a billion phones when others expected a fraction of that.October 10 at 1:00 AM | Stansberry Research (Ad)Is UroGen’s (URGN) Commercial Engine Strong Enough To Fund Its Pipeline Ambitions?September 23, 2026 | finance.yahoo.comInsider Selling: Urogen Pharma (NASDAQ:URGN) Insider Sells $37,383.32 in StockSeptember 10, 2026 | insidertrades.comUrogen Pharma: Upside After Bladder Cancer LaunchSeptember 9, 2026 | seekingalpha.comUroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 4, 2026 | globenewswire.comUroGen Pharma to Present at Upcoming Investor ConferencesSeptember 2, 2026 | globenewswire.comSee More Headlines URGN Stock Analysis - Frequently Asked Questions How have URGN shares performed this year? Urogen Pharma's stock was trading at $23.42 on January 1st, 2026. Since then, URGN stock has increased by 57.3% and is now trading at $36.83. How were Urogen Pharma's earnings last quarter? Urogen Pharma (NASDAQ:URGN) released its quarterly earnings data on Wednesday, August, 5th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by $0.02. The firm had revenue of $72.46 million for the quarter, compared to analyst estimates of $63.55 million. Read the conference call transcript. When did Urogen Pharma IPO? Urogen Pharma (URGN) raised $58 million in an initial public offering on Thursday, May 4th 2017. The company issued 4,473,373 shares at a price of $12.00-$14.00 per share. Jefferies and Cowen and Company acted as the underwriters for the IPO and Raymond James and Oppenheimer were co-managers. How do I buy shares of Urogen Pharma? Shares of URGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Urogen Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Urogen Pharma investors own include Voyager Therapeutics (VYGR), AUO (AUOTY), Waste Connections (WCN), American Water Works (AWK), The RMR Group (RMR), DiamondRock Hospitality (DRH) and Triple Flag Precious Metals (TFPM). Company Calendar Last Earnings8/05/2026Today10/10/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (6m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 URGN's financial health is in the Green zone, according to TradeSmith. URGN has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:URGN CIK1668243 Webwww.urogen.com Phone(646) 768-9780FaxN/AEmployees291Year Founded2004Price Target and Rating Average Price Target for Urogen Pharma$52.38 High Price Target$75.00 Low Price Target$33.00 Potential Upside/Downside+42.2%Consensus RatingModerate Buy Rating Score (0-4)2.70 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($1.98) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$153.49 million Net Margins-51.73% Pretax Margin-51.98% Return on EquityN/A Return on Assets-43.79% Debt Debt-to-Equity RatioN/A Current Ratio3.80 Quick Ratio3.41 Sales & Book Value Annual Sales$109.79 million Price / Sales16.40 Cash FlowN/A Price / Cash FlowN/A Book Value($2.25) per share Price / Book-16.37Miscellaneous Outstanding Shares48,880,000Free Float46,535,000Market Cap$1.80 billion OptionableOptionable Beta1.57 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:URGN) was last updated on 10/10/2026 by MarketBeat.com Staff. From Our PartnersThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredThis high yielding “gold annuity” is starting to move…Garrett Goggin, a 20+ year gold analyst, has called major moves before: Montage Gold up 2,567%, G2 Goldfields ...Golden Portfolio | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredA simple options setup that cuts through the noiseIan Cooper says most options traders overcomplicate the process, juggling countless indicators, strategies, an...TradeWins | SponsoredNew Chip takes minutes, not daysGeorge Gilder believes today's AI data centers could become tomorrow's typewriters - replaced by a single wafe...Eagle Publishing | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredThe only 5 stocks that matterSpaceX's IPO reportedly minted 4,400 new millionaires, and OpenAI is said to be eyeing a 1 trillion dollar IPO...TradeSmith | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Urogen Pharma Please log in to your account or sign up in order to add this asset to your watchlist. Share Urogen Pharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
